Oramed Initiates Patient Recruitment for a New Clinical Trial in Israel of its Oral Insulin Drug ORMD-0801 in the Treatment of Type 1 Diabetes
- Category: Proteins and Peptides
- Published on Wednesday, 21 August 2013 15:43
- Hits: 989
JERUSALEM, Israel I August 21, 2013 I Oramed Pharmaceuticals Inc. (ORMP) ( http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule, ORMD-0801 for patients with type 1 diabetes mellitus (T1DM) in Israel.
"We are very excited to continue our development of ORMD-0801 for this high-need indication. We have been encouraged by our successful T1DM trials to date and we look forward to the commencement of this study," commented Oramed CEO Nadav Kidron.
Prior clinical studies have shown that ORMD-0801 administered to T1DM patients just prior to a meal effectively kept their blood sugar levels stable. The results of one such trial were published earlier this year in the international, peer-reviewed journal PLOS ONE. The research article titled, "Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study," can be accessed on the publication's site: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0059524
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 Diabetes. The Company's corporate and R&D headquarters are based in Jerusalem.
SOURCE: Oramed Pharmaceuticals